Response to 'The end of the dosage of 6 Thioguanine nucleotides? Not so sure…'.
暂无分享,去创建一个
P. Higgins | Ji Zhu | A. Waljee | U. Balis | Yiwei Zhang | R. Stidham | K. Sauder | Anand Patel | Sandeep Segar
[1] X. Roblin,et al. The End of the Dosage of 6-Thioguanine Nucleotides? Not so Sure…. , 2018, Journal of Crohn's & Colitis.
[2] P. Higgins,et al. External Validation of a Thiopurine Monitoring Algorithm on the SONIC Clinical Trial Dataset , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[3] Siddharth Singh,et al. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. , 2017, Gastroenterology.
[4] P. Higgins,et al. Machine Learning Algorithms for Objective Remission and Clinical Outcomes with Thiopurines , 2017, Journal of Crohn's & colitis.
[5] E. Seidman,et al. Therapeutic drug monitoring in inflammatory bowel disease , 2014, Annals of gastroenterology.
[6] Christopher F. Martin,et al. Randomised clinical trial: individualised vs. weight‐based dosing of azathioprine in Crohn's disease , 2014, Alimentary pharmacology & therapeutics.
[7] F. Casellas,et al. Thiopurine methyl‐transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine‐treated inflammatory bowel disease patients , 2011, Alimentary pharmacology & therapeutics.
[8] V. Armstrong,et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. , 2007, Clinical chemistry.